A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

NCT06761586 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Patient recruitment problems

Conditions

Select Relapsed/Refractory Lymphoid Malignancies

Interventions

DRUG: AUR104

Sponsor

Aurigene Discovery Technologies Limited